Clinical trial · Observational
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
NCT03690895CI-TRIAL-00035092LCPVIHcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims at describing survival rates over time (Kaplan-Meier estimator) in patients suffering from AIDS-related primary central nervous system lymphoma who were diagnosed from 1996 to 2014 and treated with infusions of high-dose methotrexate and combined antiretroviral therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AIDS Related Lymphoma | AIDS-Related Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Central Nervous System Lymphoma | Central Nervous System Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Retrospective survival analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cases
- interventionNames
- Other: Retrospective survival analysis
Primary outcomes (1)
- measure
- Median duration of survival after diagnosis of lymphoma (years)
- timeFrame
- At the time of systematic files review (jan 2014) - average follow-up 7 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * HIV infection * AIDS-related primary central nervous system lymphoma * treated with at least one infusion of methotrexate and combine antiretroviral therapy Exclusion Criteria: * prior non-Hodgkin lymphoma
References
Publications (0)
Data not yet available
No reference posted for this study.